PMID- 15536140
OWN - NLM
STAT- MEDLINE
DCOM- 20050131
LR  - 20101118
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 38
IP  - 12
DP  - 2004 Dec
TI  - Role of low-molecular-weight heparin in invasive management of non-ST-elevation 
      acute coronary syndromes.
PG  - 2094-104
AB  - OBJECTIVE: To review the available literature addressing the role of 
      low-molecular-weight heparin (LMWH) as an alternative to unfractionated heparin 
      (UFH) in percutaneous coronary intervention (PCI) for treatment of 
      non-ST-elevation acute coronary syndromes (NSTEACS). DATA SOURCES: A MEDLINE 
      search (1966-March 2004) identified pertinent articles using the key words acute 
      coronary syndromes, unstable angina, non-ST-elevation myocardial infarction, 
      low-molecular-weight heparin, enoxaparin, dalteparin, glycoprotein IIb/IIIa 
      receptor antagonists, abciximab, tirofiban, eptifibatide, percutaneous 
      transluminal coronary angioplasty, and percutaneous coronary intervention. The 
      references of these articles were reviewed for additional pertinent references. 
      STUDY SELECTION AND DATA EXTRACTION: All human trials of LMWH in PCI for 
      treatment of NSTEACS were evaluated. All pertinent studies were included in the 
      review. DATA SYNTHESIS: Administration of LMWH with or without a glycoprotein 
      IIb/IIIa inhibitor during PCI appears to be similar to UFH in terms of efficacy. 
      LMWH, especially in combination with a glycoprotein IIb/IIIa inhibitor, may 
      increase risk of bleeding compared with UFH. CONCLUSIONS: Available clinical 
      trials do not provide definitive evidence to suggest superiority of LMWH over UFH 
      when managing NSTEACS during PCI; however, dosing strategies are available if an 
      LMWH is to be used in this setting.
FAU - Moser, Lynette R
AU  - Moser LR
AD  - Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health 
      Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201-2427, USA.
FAU - Kalus, James S
AU  - Kalus JS
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20041109
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
SB  - IM
EIN - Ann Pharmacother. 2005 Jan;39(1):201. Dosage error in article text
EIN - Ann Pharmacother. 2005 Jan;39(1):201. PMID: 15678581
MH  - Acute Disease
MH  - Angioplasty, Balloon, Coronary
MH  - Coronary Disease/*drug therapy/physiopathology/surgery
MH  - Fibrinolytic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Heparin/adverse effects/pharmacology/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/pharmacology/*therapeutic use
MH  - Humans
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
RF  - 48
EDAT- 2004/11/13 09:00
MHDA- 2005/02/03 09:00
CRDT- 2004/11/13 09:00
PHST- 2004/11/13 09:00 [pubmed]
PHST- 2005/02/03 09:00 [medline]
PHST- 2004/11/13 09:00 [entrez]
AID - aph.1E176 [pii]
AID - 10.1345/aph.1E176 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2004 Dec;38(12):2094-104. doi: 10.1345/aph.1E176. Epub 2004 Nov 
      9.